Colorado pot legalization: 30 questions (and answers)

Font ResizePoliticsBy John Ingold
The Denver Postdenverpost.comPosted: 12/13/2012 10:43:02 AM MSTDecember 13, 2012 8:52 PM GMTUpdated: 12/13/2012 01:52:59 PM MST


View the Original article

Number of Colorado concealed-carry gun permits skyrockets

Font ResizeLocal NewsBy Ryan Parker
The Denver Postdenverpost.comPosted: 12/13/2012 11:51:02 AM MSTDecember 13, 2012 9:16 PM GMTUpdated: 12/13/2012 02:16:34 PM MST


View the Original article

I-25 closed between Speer and I-70 overnight Friday and Saturday

Font ResizeLocal NewsBy Ryan Parker
The Denver Postdenverpost.comPosted: 12/13/2012 11:56:41 AM MSTDecember 13, 2012 9:32 PM GMTUpdated: 12/13/2012 02:32:23 PM MST

Interstate 25 will be closed in both directions for long periods this weekend, potentially detouring travelers headed to the high country Saturday and Sunday morning.

The highway will be closed in both directions between Speer Boulevard and Interstate 70 from 11 p.m. Friday to 8 a.m. Saturday, and 11 p.m. Saturday to 5:30 a.m. Sunday, Colorado Department of Transportation spokesman Mark Aultman said.

The closures are a result of work on the 15th Street bridge replacement project, Aultman said.

In addition, 38th Avenue between Fox and Inca streets will be closed from 3 a.m. until noon Saturday in order to place commuter rail bridge girders over the roadway, according to RTD.

Ryan Parker: 303-954-2409, rparker

View the Original article

Blazing scrap-metal yard could be seen from a mile away

Font ResizeLocal NewsThe Denver Postdenverpost.comPosted: 12/13/2012 12:08:22 PM MSTDecember 13, 2012 9:32 PM GMTUpdated: 12/13/2012 02:32:25 PM MST


View the Original article

Elevated rail, levitating cars pitched to ease I-70 ski-area travel

Font ResizeTransportationBy Monte Whaley
The Denver Postdenverpost.comPosted: 12/13/2012 01:31:25 PM MSTDecember 13, 2012 9:36 PM GMTUpdated: 12/13/2012 02:36:12 PM MST


View the Original article

Suspensions for Denver cops who filmed their boss are reinstated

Font ResizeCops and CourtsBy Tom McGhee
The Denver Postdenverpost.comPosted: 12/13/2012 02:32:43 PM MSTDecember 13, 2012 9:36 PM GMTUpdated: 12/13/2012 02:36:39 PM MST

Denver's Civil Service Commission has reinstated the suspensions of two police officers who surreptitiously taped a superior, overturning a hearing officer's ruling that reduced their penalties.

In the taping case, former Safety Manager Charles Garcia suspended Sgt. Brian O'Neill for 30 days without pay for surreptitiously filming Cmdr. John Burbach, head of the Police Department's internal-affairs bureau.

O'Neill was trying to expose what he believed was bias against his officers.

Lt. Daren Ciempa lost 40 days of pay for giving O'Neill the go-ahead to make the video recording.

Hearing officer Rhonda Rhodes found that the two "exercised poor judgment" but that "no rule, regulation or provision of Denver Police Department Operations Manual explicitly prohibits the investigative conduct" for which they were disciplined.

"The commissioners' decision reinstates the full departmental order of disciplinary action as initially issued by the former manager of safety, for both officers," Commission staff member Brian Kellogg said in an email.

The officers can appeal the decision to Denver District Court.

Tom McGhee: 303-954-1671, tmcghee

View the Original article

Pixmania founder joins Paddy Power board

Paddy Power has appointed Ulric Jerome as a non-executive director and as a member of the audit committee.

He was a founding partner and executive director of Pixmania, the only pan-European online retailer of digital photographic and consumer electronic goods.

At 3:18pm: (LON:PAP) Paddy Power share price was

View the Original article

Pixmania founder joins Paddy Power board

Paddy Power has appointed Ulric Jerome as a non-executive director and as a member of the audit committee.

He was a founding partner and executive director of Pixmania, the only pan-European online retailer of digital photographic and consumer electronic goods.

At 3:18pm: (LON:PAP) Paddy Power share price was

View the Original article

AstraZeneca drug fails to meet objective

A phase IIb study on AstraZeneca rheumatoid arthritis drug fostamatinib failed to meet one of its primary objectives.

OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD intolerant or had an inadequate response to DMARDs and were randomised to receive fostamatinib as a monotherapy, adalimumab as a monotherapy, or placebo.

Three dose regimens of fostamatinib were evaluated in OSKIRA-4: 100mg twice daily, 100mg twice daily for a month followed by 150mg once daily, and 100mg twice daily for a month followed by 100mg once daily.

OSKIRA-4 had two primary objectives - a superiority comparison to placebo at six weeks and a non-inferiority analysis against adalimumab monotherapy at 24 weeks as measured by change from baseline in DAS28 score (a composite endpoint assessing signs and symptoms of RA).

In the OSKIRA-4 study, fostamatinib as a monotherapy met the first primary objective, showing a statistically significant superior DAS28 score change from baseline compared to placebo at six weeks at the 100mg twice daily dose and the 100mg twice daily for a month followed by 150mg once daily dose, but not at the 100mg twice daily for a month followed by 100mg once daily dose.

The OSKIRA-4 study did not meet its second primary objective as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28.

The safety and tolerability findings for fostamatinib as reported in the OSKIRA-4 study were generally consistent with those previously observed in the TASKi Phase II programme.

At 3:26pm: (LON:AZN) AstraZeneca share price was -89.25p at 2953.25p

LSE:AZN Add new comment Recent Features Viewpoint: Good reasons for sticking with corporate bonds How to be a tax-efficient investor Should I take a cash lump sum or a pension? UK Select's Brazier predicts high returns on UK shares Viewpoint: Investment challenges and opportunities in 2013 Most-read this week How do I make regular income from

View the Original article

AstraZeneca drug fails to meet objective

A phase IIb study on AstraZeneca rheumatoid arthritis drug fostamatinib failed to meet one of its primary objectives.

OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD intolerant or had an inadequate response to DMARDs and were randomised to receive fostamatinib as a monotherapy, adalimumab as a monotherapy, or placebo.

Three dose regimens of fostamatinib were evaluated in OSKIRA-4: 100mg twice daily, 100mg twice daily for a month followed by 150mg once daily, and 100mg twice daily for a month followed by 100mg once daily.

OSKIRA-4 had two primary objectives - a superiority comparison to placebo at six weeks and a non-inferiority analysis against adalimumab monotherapy at 24 weeks as measured by change from baseline in DAS28 score (a composite endpoint assessing signs and symptoms of RA).

In the OSKIRA-4 study, fostamatinib as a monotherapy met the first primary objective, showing a statistically significant superior DAS28 score change from baseline compared to placebo at six weeks at the 100mg twice daily dose and the 100mg twice daily for a month followed by 150mg once daily dose, but not at the 100mg twice daily for a month followed by 100mg once daily dose.

The OSKIRA-4 study did not meet its second primary objective as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28.

The safety and tolerability findings for fostamatinib as reported in the OSKIRA-4 study were generally consistent with those previously observed in the TASKi Phase II programme.

At 3:26pm: (LON:AZN) AstraZeneca share price was -89.25p at 2953.25p

LSE:AZN Add new comment Recent Features Viewpoint: Good reasons for sticking with corporate bonds How to be a tax-efficient investor Should I take a cash lump sum or a pension? UK Select's Brazier predicts high returns on UK shares Viewpoint: Investment challenges and opportunities in 2013 Most-read this week How do I make regular income from

View the Original article

AstraZeneca drug fails to meet objective

A phase IIb study on AstraZeneca rheumatoid arthritis drug fostamatinib failed to meet one of its primary objectives.

OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD intolerant or had an inadequate response to DMARDs and were randomised to receive fostamatinib as a monotherapy, adalimumab as a monotherapy, or placebo.

Three dose regimens of fostamatinib were evaluated in OSKIRA-4: 100mg twice daily, 100mg twice daily for a month followed by 150mg once daily, and 100mg twice daily for a month followed by 100mg once daily.

OSKIRA-4 had two primary objectives - a superiority comparison to placebo at six weeks and a non-inferiority analysis against adalimumab monotherapy at 24 weeks as measured by change from baseline in DAS28 score (a composite endpoint assessing signs and symptoms of RA).

In the OSKIRA-4 study, fostamatinib as a monotherapy met the first primary objective, showing a statistically significant superior DAS28 score change from baseline compared to placebo at six weeks at the 100mg twice daily dose and the 100mg twice daily for a month followed by 150mg once daily dose, but not at the 100mg twice daily for a month followed by 100mg once daily dose.

The OSKIRA-4 study did not meet its second primary objective as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28.

The safety and tolerability findings for fostamatinib as reported in the OSKIRA-4 study were generally consistent with those previously observed in the TASKi Phase II programme.

At 3:26pm: (LON:AZN) AstraZeneca share price was -89.25p at 2953.25p

LSE:AZN Add new comment Recent Features Viewpoint: Good reasons for sticking with corporate bonds How to be a tax-efficient investor Should I take a cash lump sum or a pension? UK Select's Brazier predicts high returns on UK shares Viewpoint: Investment challenges and opportunities in 2013 Most-read this week How do I make regular income from

View the Original article

AstraZeneca drug fails to meet objective

A phase IIb study on AstraZeneca rheumatoid arthritis drug fostamatinib failed to meet one of its primary objectives.

OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD intolerant or had an inadequate response to DMARDs and were randomised to receive fostamatinib as a monotherapy, adalimumab as a monotherapy, or placebo.

Three dose regimens of fostamatinib were evaluated in OSKIRA-4: 100mg twice daily, 100mg twice daily for a month followed by 150mg once daily, and 100mg twice daily for a month followed by 100mg once daily.

OSKIRA-4 had two primary objectives - a superiority comparison to placebo at six weeks and a non-inferiority analysis against adalimumab monotherapy at 24 weeks as measured by change from baseline in DAS28 score (a composite endpoint assessing signs and symptoms of RA).

In the OSKIRA-4 study, fostamatinib as a monotherapy met the first primary objective, showing a statistically significant superior DAS28 score change from baseline compared to placebo at six weeks at the 100mg twice daily dose and the 100mg twice daily for a month followed by 150mg once daily dose, but not at the 100mg twice daily for a month followed by 100mg once daily dose.

The OSKIRA-4 study did not meet its second primary objective as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28.

The safety and tolerability findings for fostamatinib as reported in the OSKIRA-4 study were generally consistent with those previously observed in the TASKi Phase II programme.

At 3:26pm: (LON:AZN) AstraZeneca share price was -89.25p at 2953.25p

LSE:AZN Add new comment Recent Features Viewpoint: Good reasons for sticking with corporate bonds How to be a tax-efficient investor Should I take a cash lump sum or a pension? UK Select's Brazier predicts high returns on UK shares Viewpoint: Investment challenges and opportunities in 2013 Most-read this week How do I make regular income from

View the Original article

AstraZeneca drug fails to meet objective

A phase IIb study on AstraZeneca rheumatoid arthritis drug fostamatinib failed to meet one of its primary objectives.

OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD intolerant or had an inadequate response to DMARDs and were randomised to receive fostamatinib as a monotherapy, adalimumab as a monotherapy, or placebo.

Three dose regimens of fostamatinib were evaluated in OSKIRA-4: 100mg twice daily, 100mg twice daily for a month followed by 150mg once daily, and 100mg twice daily for a month followed by 100mg once daily.

OSKIRA-4 had two primary objectives - a superiority comparison to placebo at six weeks and a non-inferiority analysis against adalimumab monotherapy at 24 weeks as measured by change from baseline in DAS28 score (a composite endpoint assessing signs and symptoms of RA).

In the OSKIRA-4 study, fostamatinib as a monotherapy met the first primary objective, showing a statistically significant superior DAS28 score change from baseline compared to placebo at six weeks at the 100mg twice daily dose and the 100mg twice daily for a month followed by 150mg once daily dose, but not at the 100mg twice daily for a month followed by 100mg once daily dose.

The OSKIRA-4 study did not meet its second primary objective as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28.

The safety and tolerability findings for fostamatinib as reported in the OSKIRA-4 study were generally consistent with those previously observed in the TASKi Phase II programme.

At 3:26pm: (LON:AZN) AstraZeneca share price was -89.25p at 2953.25p

LSE:AZN Add new comment Recent Features Viewpoint: Good reasons for sticking with corporate bonds How to be a tax-efficient investor Should I take a cash lump sum or a pension? UK Select's Brazier predicts high returns on UK shares Viewpoint: Investment challenges and opportunities in 2013 Most-read this week How do I make regular income from

View the Original article

AstraZeneca drug fails to meet objective

A phase IIb study on AstraZeneca rheumatoid arthritis drug fostamatinib failed to meet one of its primary objectives.

OSKIRA-4 was a six month study evaluating improvements in signs and symptoms of RA in 280 patients who had never previously used a disease-modifying anti-rheumatic drug (DMARD), were DMARD intolerant or had an inadequate response to DMARDs and were randomised to receive fostamatinib as a monotherapy, adalimumab as a monotherapy, or placebo.

Three dose regimens of fostamatinib were evaluated in OSKIRA-4: 100mg twice daily, 100mg twice daily for a month followed by 150mg once daily, and 100mg twice daily for a month followed by 100mg once daily.

OSKIRA-4 had two primary objectives - a superiority comparison to placebo at six weeks and a non-inferiority analysis against adalimumab monotherapy at 24 weeks as measured by change from baseline in DAS28 score (a composite endpoint assessing signs and symptoms of RA).

In the OSKIRA-4 study, fostamatinib as a monotherapy met the first primary objective, showing a statistically significant superior DAS28 score change from baseline compared to placebo at six weeks at the 100mg twice daily dose and the 100mg twice daily for a month followed by 150mg once daily dose, but not at the 100mg twice daily for a month followed by 100mg once daily dose.

The OSKIRA-4 study did not meet its second primary objective as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28.

The safety and tolerability findings for fostamatinib as reported in the OSKIRA-4 study were generally consistent with those previously observed in the TASKi Phase II programme.

At 3:26pm: (LON:AZN) AstraZeneca share price was -89.25p at 2953.25p

LSE:AZN Add new comment Recent Features Viewpoint: Good reasons for sticking with corporate bonds How to be a tax-efficient investor Should I take a cash lump sum or a pension? UK Select's Brazier predicts high returns on UK shares Viewpoint: Investment challenges and opportunities in 2013 Most-read this week How do I make regular income from

View the Original article

Viewpoint: Good reasons for sticking with corporate bonds

The record low yields seen on corporate bonds still have the scope to go lower. However caution is required in this kind of environment and that careful credit selection, diversification and sound liquidity management is needed.

These concerns are valid, but the recent hysteria around corporate bonds, and in particular market liquidity, is exaggerated in my opinion. I believe that a conservatively run corporate bond portfolio with prudent liquidity management and access to good credit research offers the best risk-return mix for investors. I also think that corporate bonds continue to play a valuable role within most well-diversified portfolios.

Of course, you may think that as manager of one of the largest funds in the Corporate Bond sector, I have a vested interest in taking this stance. I would disagree, however. The position I am in ensures that I constantly think about these issues and the best methods to tackle the current challenging environment.

Yields on investment-grade bonds are at record lows. I think investors are right to question how low they can go, regardless of the robust corporate fundamentals that support credit.

My view is that they can go quite a bit lower because the environment of "financial repression" we are in today is likely to continue for some time. That is because central bankers and politicians remain welded to austerity and ultra loose monetary policy. It's understandable - they are eager to improve fiscal balances and avoid prolonged economic contraction. It is likely that this will extend the low-growth, low-inflation and low-interest-rate environment we see today with significant tail risks attached.

View the Original article

Markets: Fed fears weigh on FTSE 100 on Thursday

Thu, 13/12/2012 - 17:05

Interactive Investor's Market Report brings you bite-sized news covering all the day's FTSE and AIM announcements, the latest on commodities, global and domestic economics, gold, oil and currencies as well as US markets. Updated throughout the day, it's the digest you can't afford to miss.

Last updated: 17:05

View the Original article

Death Star Petition Meets White House Goal

A Growing Water Deficit in the West The Internet Turf War Barbara Walters Asks Chris Christie About Weight, Good News for Elizabeth Warren, and More Assad Fires Scud Missiles at Rebels, U.S. Reports The Rich, Conservative Push for Right-to-Work (Video)
NASA Announces World Won’t End Dec. 21, 2012 Sarah Silverman Pro-Choice Video Tells ‘Bros’ to Stand Up for the Ladies Watch: Fox News Contributor Gets Punched in Face During Union Protest The Revolution Continues in Challenge to Morsi
Regulate Dissent in Hong Kong, Jackie Chan Says
Fighting Manifest Destiny
By Jonathan Yardley Glenn Greenwald Condemns ‘Zero Dark Thirty’ Torture Porn
Psy Shames Himself With Unqualified Apology (Video)
By Alexander Reed Kelly
The Questions Education Reformers Aren’t Asking
Dig led by Mike Rose

Gore Vidal: His Life and Legacy
Dig led by Truthdig Staff

advertisement

-->
Why School?By Mike Rose

advertisement

-->
The Irony of Manifest Destiny: The Tragedy of America’s Foreign PolicyBy William Pfaff
$16.50

advertisement

-->
Jr. Spaghetti Tank$21

  Email    Print    Share

Tweet Posted on Dec 13, 2012 Flickr/Matt Grommes

May the Force be with them. A petition on The White House’s “We the People” site calling to secure funding and resources for the creation of a Death Star has gotten the 25,000 signatures it needs to elicit a response from the Obama administration.

As BuzzFeed noted, “The White House petition is now quite operational.”

Here’s what the official petition calls for:

Those who sign here petition the United States government to secure funding and resources, and begin construction on a Death Star by 2016.

By focusing our defense resources into a space-superiority platform and weapon system such as a Death Star, the government can spur job creation in the fields of construction, engineering, space exploration, and more, and strengthen our national defense.

The petitioner makes a solid case for the building of Death Star: job creation; defense; American superiority in outer space. Sounds pretty good, right?

However, at an estimated cost of $852 quadrillion—roughly 13,000 times the gross domestic product of the entire world—a Death Star may be out of reach financially for the budget-strapped U.S. government.

So clearly Admiral Ackbar would say it’s a fiscal cliff trap.

—Posted by Tracy Bloom.

More Below the Ad

Advertisement

TAGS: admiral ackbar barack obama budget death star death star petition economy fiscal cliff government it's a trap obama administration star wars we the people site white house



Related Entries Obamacare Begins Ground Zero in the Land of Opportunity Which Path for the Right? Barbara Walters Asks Chris Christie About Weight, Good News for Elizabeth Warren, and More

Email to a friend

Get truth delivered to
your inbox every week.

Previous item: A Growing Water Deficit in the West

New and Improved Comments

If you have trouble leaving a comment, review this help page. Still having problems? Let us know. If you find yourself moderated, take a moment to review our comment policy.

Please enable JavaScript to view the comments powered by Disqus.Get Truthdig in your inbox

Newsletter

Become a Fan

Follow Us

Subscribe

     
       #donation_div {display:none;}.popup {background:#FFF; border:1px solid #333; padding:1px;}.popup-header {height:65px; padding: 30px 40px 10px 50px;}.popup-header h2 {margin:0; padding:0; font-size:18px; float:left;}.popup-header .close-link {float:right; font-size:11px;}.popup-body {padding: 20px 70px 20px 50px;}a {color: #990000;}Close

Give the gift of independent journalism.

Support Truthdig by making a donation of at least $25 in someone's name, and we'll send him or her a signed letter of appreciation from our publisher.

With your support, we've been able to pay writers such as Chris Hedges, Col. Ann Wright, Mr. Fish and Nomi Prins.

We've sent reporters around the world, from Afghanistan to Cairo to Cuba.

Thanks to you, our mission to find and publish a range of insightful opinion and analysis from a progressive point of view continues.

Support Truthdig

HOME|Digs|Reports|Arts & Culture|Uncovered|Ear to the Ground|A/V Booth|Cartoons
Tags|Bazaar|Podcast|About Us|Contact Us|User Agreement|Privacy Policy|FAQ: Comments and Moderation | Google+ Google+
A Progressive Journal of News and Opinion. Editor, Robert Scheer. Publisher, Zuade Kaufman.
© 2012 Truthdig, LLC. All rights reserved. Web site development by Hop Studios 

View the Original article

NASA Announces World Won’t End Dec. 21, 2012

NASA Announces World Won’t End Dec. 21, 2012 -Truthdig .column > div, .eartotheground > div, .uncovered > div, .report > div, .interview > div, .arts_culture > div, .avbooth > div, .dig > div, .cartoon > div, .podcast > div, .margin {padding: 10px 10px 20px 10px;margin: 0 0 0 0px;border-bottom: 1px dashed #999999;}/*\*//*/ @import "http://www.truthdig.com/?css=home/site_styles_mac.v.1314771156";/**/body div#share_footer {margin-bottom: 30px;}body div#instory_newsletter_signup {margin-top: 30px;}.nav {font-size:90%;} December 13, 2012
Log in / Register

Text Size

HOMEEar to the GroundLarry's ListPolitics TodayAll Ear to the groundColumnsBill BoyarskyJuan ColeMarcia Alesan DawkinsAmy GoodmanChris HedgesRobert ScheerRichard SchickelCol. Ann WrightTruthdigger of the WeekMoreCartoonsMr. Fish CartoonsAll CartoonsArts & CultureAuthor InterviewBook ExcerptsBook ReviewsEssaysFilm ReviewsTheater ReviewsDigsShopTruthdig MerchandiseTruthdig BooksAuthor BooksRobert Scheer BooksChris Hedges BooksMr. Fish T-shirtsMr. Fish PrintsMultimediaA/V BoothTruthdig RadioPhoto EssaysPodcastsQ&A: Live ChatsAdvertiseDonateAboutdiv#src_container {width: 175px;background: #b59d91;height: 24px;padding: 5px;display: block;float: right;margin-top: 6px;z-index: 2;}#src_container input {width: 137px;height: 23px;border: 1px solid #5b5b5b;padding: 5px;}input#src_btn_raquo {width: 30px;height: 24px;background-color: #6f4434;color: #fff;border: none;}>" id="src_btn_raquo">Trending:     bradley manning     chris hedges     education     israel     jon stewart Israel's Apartheid Deepens, Along With Its Global Isolation

The Trials of Bradley Manning

Jon Stewart Nearly Quit 'The Daily Show' Because of 'Asshole' Colleagues

Obamacare Begins

Ground Zero in the Land of Opportunity

The Answer Is Blowing in the Wind

Hamas

The X Leader

50 Shades

Not So Wise Men

The Botox Solution
By Jeremiah Goulka, TomDispatch Obamacare Begins
By Bill Boyarsky Ground Zero in the Land of Opportunity
By Mike Rose A Right Royal Whippersnapper: Why Things Will Never Change in Britain
By Jessica Ings and Charlie Williams
Death Star Petition Meets White House Goal A Growing Water Deficit in the West The Internet Turf War Barbara Walters Asks Chris Christie About Weight, Good News for Elizabeth Warren, and More Assad Fires Scud Missiles at Rebels, U.S. Reports The Rich, Conservative Push for Right-to-Work (Video)
NASA Announces World Won’t End Dec. 21, 2012 Sarah Silverman Pro-Choice Video Tells ‘Bros’ to Stand Up for the Ladies Watch: Fox News Contributor Gets Punched in Face During Union Protest The Revolution Continues in Challenge to Morsi
Regulate Dissent in Hong Kong, Jackie Chan Says
Fighting Manifest Destiny
By Jonathan Yardley Glenn Greenwald Condemns ‘Zero Dark Thirty’ Torture Porn
Psy Shames Himself With Unqualified Apology (Video)
By Alexander Reed Kelly
The Questions Education Reformers Aren’t Asking
Dig led by Mike Rose

Gore Vidal: His Life and Legacy
Dig led by Truthdig Staff

advertisement

-->
History’s Greatest HeistBy Sean McMeekin
$27.36

advertisement

-->
Voices From the Other Side: An Oral History of Terrorism Against CubaBy Keith Bolender
$21.00

advertisement

-->
Jr. Hoodie$35

  NASA Announces World Won’t End Dec. 21, 2012 Email    Print    Share

Tweet Posted on Dec 13, 2012 screenshot

How confident is NASA in its prediction that the world will not end Dec. 21, 2012, the day the Mayan calendar runs out? Very. The space agency has already released a video explaining why the world didn’t end Dec. 21. The video, titled “Why the World Didn’t End Yesterday,” was originally scheduled to be released Dec. 22.

The Guardian:

The prediction that the world would end four days before Christmas 2012 – potentially wreaking havoc with gift buying and travel plans – is a long-standing misconception, Nasa explains.

An accompanying post on the agency’s website, titled Beyond 2012: Why the World Won’t End, says that 21 December this year has been labelled as the end of all things because the Mayan calendar ends on this date.

But “just as the calendar you have on your kitchen wall does not cease to exist after December 31, the Mayan calendar does not cease to exist on December 21, 2012,” Nasa says. Instead, it just starts over again.

Advertisement

Read more

NASA notes on its website that it knows “of no threat associated with 2012.” The agency adds: “For any claims of disaster or dramatic changes in 2012, where is the science? Where is the evidence? There is none, and for all the fictional assertions, whether they are made in books, movies, documentaries or over the Internet, we cannot change that simple fact. There is no credible evidence for any of the assertions made in support of unusual events taking place in December 2012.”

A little food for thought for anyone convinced the world will end next week.

—Posted by Tracy Bloom.

TAGS: 122112 2012 december 21 2012 doomsday end of the world mayan calendar nasa



Related Entries Which Path for the Right? The Peril of a Sentient GOP The Guardian Names Bradley Manning Its 2012 ‘Person of the Year’ In Baseless Persecution of Rice, Republican Reputations Will Sink

Email to a friend

Get truth delivered to
your inbox every week.

Previous item: Sarah Silverman Pro-Choice Video Tells ‘Bros’ to Stand Up for the Ladies

New and Improved Comments

If you have trouble leaving a comment, review this help page. Still having problems? Let us know. If you find yourself moderated, take a moment to review our comment policy.

Please enable JavaScript to view the comments powered by Disqus.Get Truthdig in your inbox

Newsletter

Become a Fan

Follow Us

Subscribe

     
       #donation_div {display:none;}.popup {background:#FFF; border:1px solid #333; padding:1px;}.popup-header {height:65px; padding: 30px 40px 10px 50px;}.popup-header h2 {margin:0; padding:0; font-size:18px; float:left;}.popup-header .close-link {float:right; font-size:11px;}.popup-body {padding: 20px 70px 20px 50px;}a {color: #990000;}Close

Give the gift of independent journalism.

Support Truthdig by making a donation of at least $25 in someone's name, and we'll send him or her a signed letter of appreciation from our publisher.

With your support, we've been able to pay writers such as Chris Hedges, Col. Ann Wright, Mr. Fish and Nomi Prins.

We've sent reporters around the world, from Afghanistan to Cairo to Cuba.

Thanks to you, our mission to find and publish a range of insightful opinion and analysis from a progressive point of view continues.

Support Truthdig

HOME|Digs|Reports|Arts & Culture|Uncovered|Ear to the Ground|A/V Booth|Cartoons
Tags|Bazaar|Podcast|About Us|Contact Us|User Agreement|Privacy Policy|FAQ: Comments and Moderation | Google+ Google+
A Progressive Journal of News and Opinion. Editor, Robert Scheer. Publisher, Zuade Kaufman.
© 2012 Truthdig, LLC. All rights reserved. Web site development by Hop Studios 

View the Original article